Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedA site-wide banner announces that NIH is transitioning to use “Super Intelligence” instead of “Artificial Intelligence,” with updates and FAQs available.SummaryDifference1%

- Check8 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check15 days agoChange DetectedThe site revision displayed in the page footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record. The prior list of documents and related metadata appears removed or hidden, indicating an access-restriction state.SummaryDifference20%

- Check56 days agoChange DetectedA funding reference, noting the 2018 U.S. NIH Grant/Contract, was added to the study identifiers. The page revision was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing the previous v3.6.4. This appears to be a minor site update and does not modify the study details.SummaryDifference0.0%

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.